Welcome to our dedicated page for Clearmind Medicine SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clearmind Medicine's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clearmind Medicine's regulatory disclosures and financial reporting.
Clearmind Medicine Inc. provides an update on its ongoing first-in-human Phase I/IIa trial of CMND-100, its non-hallucinogenic MEAI-based compound being studied for Alcohol Use Disorder (AUD). Principal investigators from Yale School of Medicine and Johns Hopkins University reported a generally positive early impression of CMND-100 and the study so far.
The webinar discussion covered study design, dose escalation, pharmacokinetics, participant experience, and potential future directions. Management highlighted the significant unmet need in AUD and emphasized that MEAI may have broader applications beyond AUD, subject to further research. Clearmind describes itself as a clinical-stage neuroplastogens pharmaceutical biotech with an intellectual property portfolio of nineteen patent families, including 32 granted patents, focused on non-hallucinogenic, second-generation neuroplastogen-derived therapeutics.
Clearmind Medicine Inc., a clinical-stage biotech focused on non-hallucinogenic neuroplastogen therapies for addiction and mental health conditions, reported that it submitted a formal response to a U.S. Department of Health and Human Services Request for Information on addiction treatment innovations under the Great American Recovery Initiative.
The company’s response centers on its proprietary MEAI-based candidate CMND-100, a non-hallucinogenic neuroplastogen being developed for Alcohol Use Disorder (AUD) and binge behaviors, highlighting a potential scalable, at-home treatment model with low abuse potential that targets neural pathways such as 5-HT1A. Clearmind notes that AUD affects roughly 10% of the U.S. population while only 1 in 10 affected individuals receive treatment, and positions MEAI-based therapies as candidates to support moderation and long-term recovery. The company also reiterates that it is a clinical-stage neuroplastogen pharmaceutical biotech with nineteen patent families, including 32 granted patents, and that its shares trade on Nasdaq under the symbol CMND.
Clearmind Medicine Inc. furnished a Form 6-K highlighting a successful formulation feasibility study for an intranasal version of its lead compound MEAI, initially targeted at alcohol use disorder. The work showed MEAI can be incorporated into a stable, fully soluble intranasal formulation, supporting continued development of this additional route of administration.
The first five paragraphs of the press release are also incorporated by reference into Clearmind’s existing Form F-3 and Form S-8 registration statements, making this R&D update part of those offerings’ disclosure record.
Clearmind Medicine Inc., a clinical-stage biotech company, reports that it has been granted a new U.S. patent, No. 12,357,590, titled “BINGE BEHAVIOR REGULATORS,” by the U.S. Patent and Trademark Office. The patent covers use of the MEAI (5-methoxy-2-aminoindane) molecule and related 2-aminoindan derivatives for regulating binge behaviors such as excessive drinking, eating and other compulsive disorders, and builds on previously issued U.S. Patent No. 12,350,242. Clearmind highlights that its intellectual property portfolio now consists of nineteen patent families, including 32 granted patents, supporting its strategy to develop non-hallucinogenic, second-generation neuroplastogen-derived therapeutics for under-treated health problems including alcohol use disorder.
Clearmind Medicine reports a key clinical milestone, completing treatment for all participants in Part A of its Phase I/II trial of CMND-100 for Alcohol Use Disorder. All 24 participants across four cohorts finished treatment according to protocol, and the company is now reviewing the data.
If results remain favorable, Clearmind plans to start the next stage of the Alcohol Use Disorder clinical program. The multicenter, FDA-regulated study is running at leading sites in the United States and Israel, including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
Clearmind is a clinical-stage biotech focused on non-hallucinogenic, second-generation neuroplastogen-derived therapeutics for under-treated conditions such as Alcohol Use Disorder. Its intellectual property portfolio includes nineteen patent families and 32 granted patents, supporting the development of CMND-100 and other candidates.
HRT Financial LP, a ten percent owner of Clearmind Medicine Inc., reported an open‑market sale of 22,139 Class A Shares at $3.306 per share. After this transaction, HRT Financial LP directly holds 81,353 Class A Shares.
Clearmind Medicine Inc. reports that it has been granted U.S. Patent No. 12,350,242, titled “BINGE BEHAVIOR REGULATORS,” by the United States Patent and Trademark Office. The patent covers compositions and methods using the company’s MEAI (5-methoxy-2-aminoindane) molecule to regulate binge behaviors such as excessive drinking, eating, and gambling.
The company states that this patent expands its global intellectual property portfolio to 32 granted patents across nineteen patent families and supports its clinical programs targeting binge-related disorders, including alcohol use disorder, and its lead candidate CMND-100. Clearmind focuses on non-hallucinogenic, second generation neuroplastogen-derived therapeutics for central nervous system conditions.
HRT Financial LP, a ten percent owner of Clearmind Medicine Inc., reported an open-market sale of 3,183 shares of Common Stock at $3.32 per share. After this transaction, HRT Financial LP directly holds 103,492 Clearmind Medicine common shares, indicating it retained the vast majority of its position.
Clearmind Medicine Inc. insider HRT Financial LP reported an open-market sale of 2,102 shares of Common Stock. The shares were sold at a price of $3.36 per share. After this transaction, HRT Financial LP directly holds 106,675 shares of Clearmind Medicine common stock.